research A10.09 Safety data of four treatment regimens in early rheumatoid arthritis patients
All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
Search
for
Sort by
Research
330-360 / 1000+ results
research New treatments for rheumatoid arthritis
New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study
Low-dose naltrexone may help reduce redness in certain scalp conditions.
research A smart polyhydroxyalkanoate-hyaluronic acid hybrid biphasic delivery platform for enhanced Alzheimer’s symptom management via sustained huperzine A release
The new delivery system improves Alzheimer's symptoms by releasing Huperzine A slowly and effectively.
research Acquired Localized Hypertrichosis Induced by Rivastigmine
An 80-year-old man grew extra hair on his forearms after starting Alzheimer's medication rivastigmine.
research Alopecia areata and ritlecitinib: Unravelling response trajectories
Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
research Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production
Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
Taking 5 alpha reductase inhibitor medication slightly increases the risk of depression, especially as you get older.
research Remote photobiomodulation ameliorates behavioral and neuropathological outcomes in a rat model of repeated closed head injury
Remote photobiomodulation improves brain injury outcomes and behavior in rats.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Major role for 5-alpha reductase inhibitors in the aging male
5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
research Arthritis drug spurs hair regrowth in alopecia patient
An arthritis drug helped a person with severe hair loss regrow their hair.
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.
research Novel 5α-reductase inhibitors unlinked to depression-like phenotypes in rat model of BPH
research A review of the sources and pharmacological research of morroniside
Morroniside has many health benefits, including protection against diabetes complications, bone and brain diseases, heart and skin issues, and it supports hair growth and reduces inflammation.
research Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.
research Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
research Bioavailability File: Bicalutamide
Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
research Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial
Memantine may slightly improve memory in people with Down syndrome, but more research is needed.
research Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Therapeutic Androgen Receptor Ligands
Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research The risk of dementia with the use of 5 alpha reductase inhibitors
Using 5 alpha reductase inhibitors may increase dementia risk in the first two years.
research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances
The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.